Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $5 | $7 | $4 | $5 |
| % Growth | -23.7% | 50.6% | -12.7% | – |
| Cost of Goods Sold | $2 | $3 | $2 | $2 |
| Gross Profit | $3 | $3 | $2 | $3 |
| % Margin | 55.6% | 51.1% | 47.7% | 55.7% |
| R&D Expenses | $0 | $0 | $3 | $1 |
| G&A Expenses | $15 | $19 | $22 | $20 |
| SG&A Expenses | $15 | $19 | $22 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $19 | $25 | $21 |
| Operating Income | -$13 | -$16 | -$23 | -$18 |
| % Margin | -255% | -244.6% | -525% | -364.2% |
| Other Income/Exp. Net | -$1 | $9 | -$6 | -$5 |
| Pre-Tax Income | -$14 | -$7 | -$30 | -$23 |
| Tax Expense | $0 | $0 | $9 | $13 |
| Net Income | -$14 | -$7 | -$39 | -$36 |
| % Margin | -275% | -111.7% | -883.6% | -725.1% |
| EPS | -0.58 | -0.31 | -1.63 | -1.53 |
| % Growth | -87.1% | 81% | -6.5% | – |
| EPS Diluted | -0.58 | -0.31 | -1.63 | -1.53 |
| Weighted Avg Shares Out | 24 | 24 | 24 | 24 |
| Weighted Avg Shares Out Dil | 24 | 24 | 24 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $3 |
| Interest Expense | $0 | $0 | $0 | $17 |
| Depreciation & Amortization | $1 | -$0 | $1 | $0 |
| EBITDA | -$17 | -$16 | -$24 | -$6 |
| % Margin | -335.3% | -244.6% | -558.9% | -114% |